相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis
Zhujun Deng et al.
CLINICAL LUNG CANCER (2021)
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
Xiuning Le et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues
Alex M. Li et al.
CANCER BIOLOGY & THERAPY (2020)
Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial
Xi Li et al.
CLINICAL CANCER RESEARCH (2020)
Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
Kang Qin et al.
BMC CANCER (2020)
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With AdvancedEGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis
Fei Chen et al.
FRONTIERS IN ONCOLOGY (2020)
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Haruhiro Saito et al.
LANCET ONCOLOGY (2019)
1480OCTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC
Q Zhou et al.
ANNALS OF ONCOLOGY (2019)
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations
Antonio Passaro et al.
CLINICAL LUNG CANCER (2019)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa et al.
LANCET ONCOLOGY (2019)
Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?
Everardo D. Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?
Everardo D. Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Overview of current systemic management of EGFR-mutant NSCLC
W. -H. Hsu et al.
ANNALS OF ONCOLOGY (2018)
Worldwide Frequency of Commonly Detected EGFR Mutations
Rondell P. Graham et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
Edurne Arriola et al.
BMC CANCER (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
On the Interpretation of the Hazard Ratio and Communication of Survival Benefit
Andreas Sashegyi et al.
ONCOLOGIST (2017)
Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis
Miaomiao Sheng et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Jeffrey C. Thompson et al.
CLINICAL CANCER RESEARCH (2016)
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
Lowell E. Schnipper et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics
Jennifer J. Wheler et al.
MOLECULAR CANCER THERAPEUTICS (2016)
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-Lun Zhang et al.
Oncotarget (2016)
VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy
Maria Schwaederle et al.
CANCER RESEARCH (2015)
Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma
Tetsuya Isaka et al.
MEDICINE (2015)
Transient Antiangiogenic Treatment Improves Delivery of Cytotoxic Compounds and Therapeutic Outcome in Lung Cancer
Sampurna Chatterjee et al.
CANCER RESEARCH (2014)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Takashi Seto et al.
LANCET ONCOLOGY (2014)
Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
Yaxiong Zhang et al.
PLOS ONE (2014)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner
Vikash P. Chauhan et al.
NATURE NANOTECHNOLOGY (2012)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals
Jian-Quan Zhu et al.
CANCER LETTERS (2008)
Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: An analytical database
Samuel Murray et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: Rationale and clinical applications for non-small-cell lung cancer
Lauren A. Byers et al.
CLINICAL LUNG CANCER (2007)
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib
Kendall D. Carey et al.
CANCER RESEARCH (2006)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth
A Narendran et al.
EXPERIMENTAL HEMATOLOGY (2003)
分享论文
